Enterprise & Finance
27 July 2022, 7:12 pm. 1 minute
Reuters completely reported that the U.S. Justice Division has opened a prison investigation into Cassava Sciences involving whether or not the biotech firm manipulated analysis outcomes for its experimental Alzheimer’s drug. The probe provides to scrutiny on the corporate from the U.S. Securities and Alternate Fee and buyers after two physicians made allegations of information manipulation and misrepresentation involving analysis underpinning the corporate’s Alzheimer’s drug, known as simufilam. Shares in Cassava fell greater than 30% after Reuters revealed the information.
Shares in Cassava fell greater than 30% after Reuters revealed the information.
Matters of Curiosity: Enterprise & Finance
Sort: Reuters Greatest
Win Sorts: Exclusivity
Story Sorts: Unique / Scoop
Media Sorts: Textual content
Buyer Affect: Important Nationwide Story